Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Materials (Basel, Switzerland)|August 4, 2017
Characterization of OT4-1 Alloy by Multi-Dome Forming TestIvan Zakhariev, Sergey Aksenov, Anton Kotov, et al.
Acta Crystallographica Section B, Structural Science, Crystal Engineering and Materials|February 7, 2022
Polymorphism, polytypism and modular aspect of compounds with the general formula A2M3(TO4)4 (A = Na, Rb, Cs, Ca; M = Mg, Mn, Fe3+, Cu2+; T = S6+, P5+): order-disorder, topological description and DFT calculationsSergey Aksenov, Andrey Antonov, Dina Deyneko, et al.
Physiological Reports|March 1, 2018
Individualized treatment strategies for hyperuricemia informed by a semi-mechanistic exposure-response model of uric acid dynamicsSergey Aksenov, Carl C Peck, Ulf G Eriksson, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 11, 2020
Modeling Tumor Growth and Treatment Resistance Dynamics Characterizes Different Response to Gefitinib or Chemotherapy in Non-Small Cell Lung CancerMario Nagase, Sergey Aksenov, Hong Yan, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 15, 2020
Longitudinal Tumor Size and Neutrophil-to-Lymphocyte Ratio Are Prognostic Biomarkers for Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With DurvalumabSergey Gavrilov, Kirill Zhudenkov, Gabriel Helmlinger, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 8, 2017
Population Exposure-Response Modeling Supported Selection of Naloxegol Doses in Phase III Studies in Patients With Opioid-Induced ConstipationNidal Al-Huniti, Hongmei Xu, Diansong Zhou, et al.
Journal of Pharmacokinetics and Pharmacodynamics|March 17, 2021
A semi-mechanistic exposure-response model to assess the effects of verinurad, a potent URAT1 inhibitor, on serum and urine uric acid in patients with hyperuricemia-associated diseasesJacob Leander, Mikael Sunnåker, Dinko Rekić, et al.
Clinical Pharmacokinetics|December 18, 2018
Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell MalignanciesHelena Edlund, Sun Ku Lee, Marilee A Andrew, et al.
Oncoimmunology|September 16, 2020
Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysisBoris Shulgin, Yuri Kosinsky, Andrey Omelchenko, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 17, 2017
Drug-disease modeling in the pharmaceutical industry - where mechanistic systems pharmacology and statistical pharmacometrics meetGabriel Helmlinger, Nidal Al-Huniti, Sergey Aksenov, et al.
Pageof 2